These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8782620)

  • 1. Weight gain in women receiving adjuvant chemotherapy for breast cancer.
    Faber-Langendoen K
    JAMA; 1996 Sep; 276(11):855-6. PubMed ID: 8782620
    [No Abstract]   [Full Text] [Related]  

  • 2. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
    Winer E
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
    [No Abstract]   [Full Text] [Related]  

  • 3. Tamoxifen in early breast cancer.
    Arriagada R
    Lancet; 1998 Aug; 352(9125):403-4. PubMed ID: 9717953
    [No Abstract]   [Full Text] [Related]  

  • 4. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
    Petrelli F; Barni S
    Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant hormonal therapy for premenopausal women with breast cancer.
    Brown RJ; Davidson NE
    Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant endocrine therapy in premenopausal women with breast cancer.
    González Martín A; de la Cruz S; Márquez R
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
    [No Abstract]   [Full Text] [Related]  

  • 7. Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?
    Bramwell VH; Pritchard KI
    Eur J Cancer; 1999 Nov; 35(12):1625-7. PubMed ID: 10674005
    [No Abstract]   [Full Text] [Related]  

  • 8. neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II.
    Pritchard KI; Levine MN; Tu D
    J Clin Oncol; 2003 Feb; 21(3):399-400. PubMed ID: 12560425
    [No Abstract]   [Full Text] [Related]  

  • 9. HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
    Ferretti G; Di Cosimo S; Giannarelli D; Carlini P; Papaldo P; Alimonti A; Fabi A; Mandalà M; Milella M; Ruggeri EM; Cognetti F
    J Clin Oncol; 2004 Feb; 22(3):568-9. PubMed ID: 14752083
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant endocrine therapy for premenopausal hormone receptor-positive breast cancer; much done, more to do.
    Higgins MJ; Wolf AC
    Oncology (Williston Park); 2009 Jan; 23(1):40, 42, 44. PubMed ID: 19283920
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
    Dellapasqua S; Colleoni M; Gelber RD; Goldhirsch A
    J Clin Oncol; 2005 Mar; 23(8):1736-50. PubMed ID: 15755982
    [No Abstract]   [Full Text] [Related]  

  • 12. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
    J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.
    Montemurro F; Del Mastro L; De Laurentiis M; Puglisi F
    Expert Rev Anticancer Ther; 2016; 16(2):211-8. PubMed ID: 26634955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian suppression for early breast cancer.
    Wilcken N; Stockler M
    Lancet; 2007 May; 369(9574):1668-70. PubMed ID: 17512837
    [No Abstract]   [Full Text] [Related]  

  • 16. [Adjuvant tamoxifen treatment in breast cancer: is 5-year treatment sufficient?].
    Andersson M; Dombernowsky P
    Ugeskr Laeger; 1997 Jun; 159(25):3968-9. PubMed ID: 9214074
    [No Abstract]   [Full Text] [Related]  

  • 17. LHRH-agonist versus chemotherapy in premenopausal breast cancer?
    Klijn JG
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S45-6. PubMed ID: 12409071
    [No Abstract]   [Full Text] [Related]  

  • 18. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
    Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML
    Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
    Semilgazov VF; Manikhas AG; Semiglazov VV; Bozhok AA; Dashian GA; Ivanov VG; Paltuev RM; Vasil'ev AG; Shchedrin DE; Ermachenkova AM; Nikitina IV; Pen'kov KD; Bessonov AA; Tabagua TT; Kolar'kova VV
    Vopr Onkol; 2011; 57(5):567-77. PubMed ID: 22238925
    [No Abstract]   [Full Text] [Related]  

  • 20. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.